for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

AzurRx BioPharma Inc

AZRX.OQ

Latest Trade

0.72USD

Change

-0.06(-7.69%)

Volume

99,741

Today's Range

0.70

 - 

0.89

52 Week Range

0.42

 - 

3.09

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Azurrx Biopharma Announces Positive Cff Dsmb Review Of Final Phase 2 Option Trial Data

Oct 17 (Reuters) - AzurRx BioPharma Inc <AZRX.O>::AZURRX BIOPHARMA ANNOUNCES POSITIVE CFF DSMB REVIEW OF FINAL PHASE 2 OPTION TRIAL DATA.AZURRX BIOPHARMA INC - NO SAFETY CONCERNS CITED FOR MS1819-SD.AZURRX BIOPHARMA - POSITIVE REVIEW SUPPORTS PLAN TO PROCEED TO HIGHER 4-GRAM DOSE OF MS1819-SD IN NEXT PHASE 2 TRIAL.AZURRX BIOPHARMA - LOOK FORWARD TO INITIATING NEXT PHASE 2 STUDY OF MS1819-SD AT HIGHER DOSE IN EARLY 2020.AZURRX BIOPHARMA - SAFETY PROFILE OF MS1819 AT 2-GRAM DOSE IN BOTH PHASE 2 STUDIES FOR CYSTIC FIBROSIS REPORTED NO SERIOUS ADVERSE EVENTS.

AzurRx Biopharma Announces Appointment Of James Sapirstein As Chief Executive Officer

Oct 10 (Reuters) - AzurRx BioPharma Inc <AZRX.O>::AZURRX BIOPHARMA ANNOUNCES APPOINTMENT OF JAMES SAPIRSTEIN AS CHIEF EXECUTIVE OFFICER.AZURRX BIOPHARMA INC - RESIGNATION OF THIJS SPOOR.AZURRX BIOPHARMA INC - SAPIRSTEIN RECENTLY SERVED AS CHIEF EXECUTIVE OFFICER AND BOARD MEMBER FOR CONTRAVIR PHARMACEUTICALS.

AzurRx Biopharma Announces Positive Results From Phase 2 Trial With MS1819 In Cystic Fibrosis Patients

Sept 25 (Reuters) - AzurRx BioPharma Inc <AZRX.O>::AZURRX BIOPHARMA ANNOUNCES POSITIVE RESULTS FROM PHASE 2 TRIAL WITH MS1819 IN CYSTIC FIBROSIS PATIENTS.AZURRX BIOPHARMA - POSITIVE SAFETY RESULTS FROM PHASE II OPTION CLINICAL TRIAL OF MS1819 FOR TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY IN CF.AZURRX BIOPHARMA - CO IS PLANNING TO MEET WITH FDA BEFORE YEAR-END TO DISCUSS PHASE IIB/III TRIAL DESIGN.

AzurRx BioPharma Says On Track To Announce Final Data Analysis Of Option Study In September 2019

Aug 13 (Reuters) - AzurRx BioPharma Inc <AZRX.O>::AZURRX BIOPHARMA REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.AZURRX BIOPHARMA INC - REMAIN ON TRACK TO ANNOUNCE FINAL DATA ANALYSIS OF OPTION STUDY IN SEPTEMBER 2019.

Azurrx Biopharma Announces Proposed Public Offering Of Common Stock

July 17 (Reuters) - AzurRx BioPharma Inc <AZRX.O>::AZURRX BIOPHARMA ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.AZURRX BIOPHARMA - TO USE NET PROCEEDS FOR RESEARCH AND DEVELOPMENT EXPENSES ASSOCIATED WITH AZURRX'S CONTINUING CLINICAL DEVELOPMENT AND TESTING OF MS1819-SD.AZURRX BIOPHARMA INC - NET PROCEEDS FROM OFFERING PRIMARILY FOR ADVANCING ITS PRECLINICAL PROGRAMS FOR AZX1103.

AzurRx BioPharma Announces Initiation Of Phase 2 Clinical Study For Ms1819-Sd

July 8 (Reuters) - AzurRx BioPharma Inc <AZRX.O>::AZURRX BIOPHARMA ANNOUNCES INITIATION OF PHASE 2 CLINICAL STUDY FOR MS1819-SD IN COMBINATION WITH STANDARD PERT FOR CYSTIC FIBROSIS PATIENTS WITH SEVERE EXOCRINE PANCREATIC INSUFFICIENCY.AZURRX BIOPHARMA INC - PRELIMINARY DATA EXPECTED IN EARLY 2020..AZURRX BIOPHARMA INC - PRELIMINARY DATA EXPECTED IN EARLY 2020..

Azurrx Biopharma Inc Files For Mixed Shelf Of Up To $50 Million

June 5 (Reuters) - AzurRx BioPharma Inc <AZRX.O>::AZURRX BIOPHARMA INC FILES FOR MIXED SHELF OF UP TO $50 MILLION – SEC FILING.

Azurrx Files Prospectus Related To Possible Resale From Time To Time Of Up To 1.6 Million Shares

April 26 (Reuters) - AzurRx BioPharma Inc <AZRX.O>::AZURRX BIOPHARMA INC - FILES PROSPECTUS RELATED TO POSSIBLE RESALE FROM TIME TO TIME OF UP TO 1.6 MILLION SHARES OF COMMON STOCK - SEC FILING.

Azurrx Biopharma Entered Note Purchase Agreement With Adec Private Equity Investments On Feb 14

Feb 20 (Reuters) - AzurRx BioPharma Inc <AZRX.O>::AZURRX BIOPHARMA - ENTERED NOTE PURCHASE AGREEMENT PURCHASE AGREEMENT WITH ADEC PRIVATE EQUITY INVESTMENTS ON FEB 14 - SEC FILING.

Azurrx Biopharma Initiates Phase II Clinical Trial Of MS1819-Sd For Cystic Fibrosis

Dec 19 (Reuters) - AzurRx BioPharma Inc <AZRX.O>::AZURRX BIOPHARMA ANNOUNCES INITIATION OF PHASE II OPTION CLINICAL TRIAL OF MS1819-SD IN CYSTIC FIBROSIS PATIENTS.AZURRX BIOPHARMA INC - PLANNED ENROLLMENT IS EXPECTED TO INCLUDE APPROXIMATELY 30 CF PATIENTS, WITH STUDY COMPLETION ANTICIPATED IN 2019.AZURRX BIOPHARMA INC - INITIAL TOP LINE DATA FROM PHASE II OPTION STUDY EXPECTED IN 2019.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up